Nobazit pills 250mg, 20pcs

Composition

1 tablet contains:

core:

Active ingredient:

N-methyl-4-benzylcarbamidopyridinium iodide (enisamium iodide) (in terms of 100% anhydrous substance) – 125.0 mg/250.0 mg

. excipients:

lactose monohydrate and 33.4 mg/66,8 mg,

microcrystalline cellulose 101 – 10.0 mg/20,0 mg,

sucrose (sugar) – 9.0 mg/18,0 mg,

povidone K-17 (Plasdone K-17) – 3.6 mg/7.2 mg,

copovidone (Plasdone S-630) – 1.4 mg/2,8 mg,

crospovidone (Polyplasdone XL-10) – 3,8 mg/ 7,6 mg,

talc – 1.9 mg/3,8 mg

calcium stearate – 1.9 mg/3,8 mg.

film cover:

Aquarius Prime BAN314047 Yellow – 6 mg/12 mg (polymer of 3.96 mg/7,92 mg, titanium dioxide – 1,3437 mg/2,6874 mg, kapril/a caprilate (Caprylic/capric triglyceride) -0,54 mg/1.08 mg, dye iron oxide yellow – 0,042 mg/0,084 mg, dye iron oxide red 0.0003 mg/mg, about 0.0006, quinoline yellow dye – 0,114 mg/0.228 mg).

Pharmacological action

Pharmacotherapeutic group: antiviral agent.

ATX Code: J05AX

Pharmacological properties

Pharmacodynamics

Enisamia iodide is an antiviral agent derived from isonicotinic acid. Effectively suppresses the action of influenza viruses and other pathogens of acute respiratory viral infections (ARVI) due to the direct (inhibitory) effect on the process of virus penetration through the cell membrane.

It has interferogenic properties and increases the concentration of endogenous interferon (interferon alpha and interferon gamma) in blood plasma by 3-4 times.

Increases the body’s resistance to viral infections.

Reduces acute clinical manifestations of viral intoxication, helps to reduce the duration of the disease.

Pharmacokinetics

After ingestion, enisamia iodide quickly enters the bloodstream, its maximum concentration in the blood is observed 2-2.5 hours after use. The half-life is 13.5-14 hours, it is metabolized in the liver, but is rapidly eliminated from the tissues (the half-life is 2-3 hours). It is excreted from the body by 90-95% in the urine in the form of metabolites.

Indications

Treatment of influenza and other acute respiratory viral infections in adults and adolescents, including as part of complex therapy.

Use during pregnancy and lactation

Contraindicated use during pregnancy and lactation.

Contraindications

Hypersensitivity to any of the components of the drug.

Lactase deficiency, lactose intolerance, glucose-galactose malabsorption.

Sucrose/isomaltase deficiency, fructose intolerance.

Children under 12 years of age, pregnancy, breast-feeding period.

The presence of allergic reactions regardless of the nature of the allergen in the anamnesis.

Severe organic liver and kidney damage.

With caution

Patients with thyroid diseases, especially with hyperthyroidism.

Side effects

Allergic reactions: hypersensitivity reactions, including skin rashes, urticaria, angioedema, pruritus.

From the gastrointestinal tract: dry and bitter taste in the mouth, swelling of the oral mucosa, hypersalivation, yellow staining of the tongue, nausea, vomiting, heartburn, abdominal pain, heaviness in the right hypochondrium, diarrhea, bloating.

Respiratory system disorders: shortness of breath, throat irritation.

In the post-marketing period, the following adverse reactions were observed in isolated cases: headache, dizziness, weakness, fluctuation of blood pressure.

If you experience any of the side effects listed in the instructions, or they get worse, or you notice any other side effects not listed in the instructions, tell your doctor.

Interaction

Interactions with other drugs have not been sufficiently studied.

NOBAZIT ® enhances the action of antibacterial and immunomodulatory agents. It is advisable to combine this drug with ascorbic acid and other vitamins. NOBAZIT® can also be administered concomitantly with recombinant interferon.

If you are using the above or other medications (including over-the-counter medications), please consult your doctor before using NOBAZIT®.

How to take, course of use and dosage

Start treatment when the first signs of the disease appear. If there is no improvement after 3 days of treatment, or if the symptoms worsen or new symptoms appear, you should consult your doctor. Use the drug only according to the indications, the method of use and in the doses indicated in the instructions.

The drug NOBAZIT® is taken orally after a meal, without chewing.

The maximum single dose is 1000 mg, the daily dose is 2000 mg.

Adults: 500 mg 3 times a day. The recommended course of treatment is 5 to 7 days.

Children from 12 years of age: 250 mg 3 times a day for 7 days.

Overdose

In case of overdose of the drug, the side effects described in the corresponding section may increase. When they appear, gastric lavage and symptomatic treatment are performed.

Description

Round biconvex tablets, film-coated, yellow in color, on a cross-section the core is from light yellow to yellow or yellow with a greenish tinge of color.

Special instructions

Caution should be exercised when prescribing the drug to patients with thyroid diseases, especially with hyperthyroidism.

Influence on the ability to drive vehicles and mechanisms

Taking enisamium iodide does not affect the ability to drive vehicles and mechanisms.

Form of production

Film-coated tablets,125 mg and 250 mg. 10 tablets in a contour cell package made of polyvinyl chloride film and aluminum foil. 20 tablets in a low-pressure poethylene jar. 1 or 2 contour cell packages or 1 jar of polymer materials together with the instructions for use are placed in a pack of cardboard.

Storage conditions

Store the contour cell package or jar in a pack, at a temperature not exceeding 25 °C.

Keep out of the reach of children.

Shelf

life is 3 years.

Do not use after the expiration date indicated on the package.

Active ingredient

Enisamia iodide

Dosage form

Tablets

Description

For adults

Indications

Flu